[Prognosis and risk factors of IgA vasculitis nephritis in children]
- PMID: 39563047
- DOI: 10.3760/cma.j.cn112140-20240709-00466
[Prognosis and risk factors of IgA vasculitis nephritis in children]
Abstract
Objective: To investigate the prognosis and risk factors of IgA vasculitis nephritis (IgAVN) in children. Methods: A retrospective cohort study was conducted. Clinical data were collected from 264 children who were pathologically diagnosed with IgAVN at Department of Pediatric Nephrology, Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and Technology, between January 2011 and December 2017. All patients had a follow-up period of more than 3 years. Clinical characteristics, renal pathology, 3-year and 5-year prognosis were analyzed. The patients were grouped based on gender, age of onset (≤6 years, >6-9 years, and >9 years), pathological classification (≤Ⅲ and>Ⅲ),whether the prognosis was complete remission at 3 and 5 years. Independent sample t-tests, ANOVA or chi-squared test were used for intergroup comparisons. Spearman correlation analysis was applied for ordinal data, and multivariate Logistic regression was used to analyze factors affecting the prognosis. Receiver operating characteristic (ROC) curve was utilized to evaluate the predictive value of these factors. Results: Of the 264 children with IgAVN, 153 were male and 111 were female, the age of onset was 8.3 (6.7, 10.3) years, 118 patients (45%) with onset age >6-9 years accounted for the highest proportion. All patients presented with skin purpura and renal involvement, primarily manifesting as hematuria and/or proteinuria. Microscopic hematuria was observed in 253 patients (95.8%), while 246 patients (93.2%) showed proteinuria. In 256 patients (97.0%), hematuria or proteinuria urinalysis was detected within 6 months of skin purpura onset, and 243 patients (92.0%) underwent renal biopsy within 6 months of renal involvement. The most common clinical subtype in 264 IgAVN children was hematuria and proteinuria (204 cases, 77.3%), with grade Ⅲ being the predominant pathological classification (181 cases, 68.6%). Among children ≤6 years old, the 3-year complete remission rate was higher in males than in females (83.9% (26/31) vs. 7/16, χ²=8.12, P=0.012). Factors independently associated with poor 5-year prognosis included time from hematuria or proteinuria urinalysis to renal biopsy >6 months, elevated serum cholesterol levels, and incomplete remission 3 years post-biopsy (OR=5.41, 1.39, 6.02, 95%CI 1.40-20.86, 1.04-1.84, 2.61-13.88, all P<0.05). The serum cholesterol has a predictive value for 5-year prognosis (P=0.020, AUC=0.62, 95%CI 0.52-0.71, Youden index=0.27, cutoff=4.37). Conclusions: For children with IgAVN aged≤6 years, the 3-year prognosis is better in males than in females. Time from hematuria or proteinuria urinalysis to renal biopsy >6 months, elevated serum cholesterol levels, and incomplete remission at 3 years post-biopsy may be independent risk factors for poor 5-year prognosis in children with IgAVN.
目的: 探讨儿童IgA血管炎肾炎(IgAVN)的预后情况及相关危险因素。 方法: 回顾性队列研究。收集2011年1月至2017年12月于华中科技大学同济医学院附属同济医院儿童肾脏专科病理诊断为IgAVN且随访时间>3年的264例患儿的临床资料,包括临床特点、病理、3年和5年的预后情况,根据性别、发病年龄(≤6岁、>6~9岁和>9岁)、国际儿童肾脏病研究组病理分级(≤Ⅲ级和>Ⅲ级)、3年和5年的预后是否完全缓解进行分组,组间比较采用独立样本t检验、方差分析或χ²检验等,等级资料的相关性采用Spearman相关性分析,采用多因素Logistic回归分析预后的影响因素,并采用受试者工作特征(ROC)曲线分析其预测价值。 结果: 264例IgAVN患儿中男153例、女111例,发病年龄为8.3(6.7,10.3)岁,>6~9岁组的患儿最多[118例(45%)]。所有患儿均有皮肤紫癜和肾脏受累,肾脏损伤以血尿和(或)蛋白尿为主要症状,其中253例(95.8%)患儿有镜下血尿表现,246例(93.2%)患儿尿检发现蛋白尿。256例(97.0%)患儿在出现皮肤紫癜6个月内发现血尿或蛋白尿,243例(92.0%)患儿在肾脏受累6个月内行肾脏穿刺活检。264例IgAVN患儿最多见的临床分型为血尿和蛋白尿型[204例(77.3%)],病理分级以Ⅲ级为主[181例(68.6%)]。男性发病年龄≤6岁患儿3年预后完全缓解率高于女性[83.9%(26/31)比7/16,χ²=8.12,P=0.012]。血尿或蛋白尿至肾活检时间>6个月、血总胆固醇水平升高、患儿肾活检后3年未完全缓解均是影响患儿5年预后的独立危险因素(OR=5.41、1.39、6.02,95%CI 1.40~20.86、1.04~1.84、2.61~13.88,均P<0.05)。血总胆固醇水平对患儿5年预后有预测价值(P=0.020,AUC=0.62,95%CI 0.52~0.71,约登指数=0.27,截断点=4.37)。 结论: 发病年龄≤6岁IgAVN患儿3年预后男性好于女性。血尿或蛋白尿至肾活检的时间>6个月、血总胆固醇水平升高、患儿肾活检后3年未完全缓解可能是IgAVN患儿5年预后的独立危险因素。.
Publication types
MeSH terms
Substances
Grants and funding
- CXPJJH11900018-2007/Hubei Chen Xiaoping Science and Technology Development Foundation Youth Science Special Fund Program
- WJ2023M004/Hubei Provincial Health Committee General Program
- YXJL-2023-0866-0329/Beijing Medical Award Foundation Program
- CXPJJH11900018‑2007/Hubei Chen Xiaoping Science and Technology Development Foundation Youth Science Special Fund Program
- YXJL‑2023‑0866‑0329/Beijing Medical Award Foundation Program
LinkOut - more resources
Full Text Sources
Miscellaneous
